Clinuvel Pharmaceuticals Limited (ASX: CUV)
Australia
· Delayed Price · Currency is AUD 12.10
-0.10 (-0.82%)
Jan 31, 2025, 4:10 PM AEST
Clinuvel Pharmaceuticals Cash Flow Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2019 - 2015 |
| Net Income | 35.64 | 30.6 | 20.88 | 24.73 | 15.05 | Upgrade
|
| Depreciation & Amortization | 1.09 | 0.74 | 0.72 | 0.82 | 0.43 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | - | 0.03 | 0.09 | - | Upgrade
|
| Stock-Based Compensation | 6.11 | 8.99 | 6.12 | 2.6 | 1.66 | Upgrade
|
| Other Operating Activities | 0.67 | -0.21 | 0.17 | 1.56 | -1.26 | Upgrade
|
| Change in Accounts Receivable | -4.02 | -6.01 | -0.11 | -9.48 | -2.46 | Upgrade
|
| Change in Inventory | -1.11 | -7.69 | 1.35 | -1.9 | 0.85 | Upgrade
|
| Change in Accounts Payable | -0.65 | 4.51 | -1.56 | - | 2.66 | Upgrade
|
| Change in Income Taxes | -0.24 | 8.81 | 7.18 | 0.1 | - | Upgrade
|
| Change in Other Net Operating Assets | 0.07 | -1.41 | -0.97 | -0.14 | 0.77 | Upgrade
|
| Operating Cash Flow | 37.05 | 36.91 | 39.87 | 19.26 | 14.19 | Upgrade
|
| Operating Cash Flow Growth | 0.38% | -7.42% | 107.00% | 35.76% | -23.12% | Upgrade
|
| Capital Expenditures | -5.58 | -1.03 | -0.43 | -0.85 | -0.89 | Upgrade
|
| Investment in Securities | -23.46 | -30.82 | - | - | - | Upgrade
|
| Investing Cash Flow | -29.03 | -31.85 | -0.43 | -0.85 | -0.89 | Upgrade
|
| Long-Term Debt Repaid | -0.35 | -0.26 | -0.27 | -0.2 | -0.24 | Upgrade
|
| Net Debt Issued (Repaid) | -0.35 | -0.26 | -0.27 | -0.2 | -0.24 | Upgrade
|
| Issuance of Common Stock | 4.16 | - | - | - | - | Upgrade
|
| Repurchase of Common Stock | -4.91 | - | - | - | - | Upgrade
|
| Common Dividends Paid | -2.47 | -1.98 | -1.24 | -1.24 | -1.22 | Upgrade
|
| Other Financing Activities | - | - | - | -0.04 | -0.02 | Upgrade
|
| Financing Cash Flow | -3.57 | -2.24 | -1.5 | -1.48 | -1.49 | Upgrade
|
| Foreign Exchange Rate Adjustments | -1.14 | 1.66 | 0.88 | -0.98 | 0.66 | Upgrade
|
| Net Cash Flow | 3.31 | 4.48 | 38.82 | 15.94 | 12.48 | Upgrade
|
| Free Cash Flow | 31.48 | 35.88 | 39.44 | 18.41 | 13.3 | Upgrade
|
| Free Cash Flow Growth | -12.28% | -9.01% | 114.25% | 38.41% | -26.92% | Upgrade
|
| Free Cash Flow Margin | 35.70% | 45.82% | 60.01% | 38.10% | 40.84% | Upgrade
|
| Free Cash Flow Per Share | 0.62 | 0.69 | 0.76 | 0.36 | 0.26 | Upgrade
|
| Cash Interest Paid | - | - | - | 0.04 | 0.02 | Upgrade
|
| Cash Income Tax Paid | 15.65 | 7.74 | - | - | - | Upgrade
|
| Levered Free Cash Flow | 23.45 | 32.33 | 33.25 | 8.06 | 9.4 | Upgrade
|
| Unlevered Free Cash Flow | 26.23 | 34.33 | 34.67 | 9.07 | 10.68 | Upgrade
|
| Change in Net Working Capital | 5.74 | 1.95 | -6.05 | 11.35 | -1.83 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.